BERKELEY, Calif., Feb. 27 /PRNewswire/ -- Bayer HealthCare today announced a charitable gift of $100,000 to the National Hemophilia Foundation (NHF) to fund activities of the National Youth Leadership Institute, a program designed to develop the next generation of leaders within the bleeding disorders community. The contribution, made by the Bayer Foundation, is one of many made each year to fund the programs of specific advocacy organizations that serve the needs of people affected by the conditions that Bayer products treat -- hemophilia, cancer, diabetes and cardiovascular disease.
Each year The National Youth Leadership Institute offers 20 - 30 selected participants an opportunity to attend two weekend training sessions, focusing on leadership development and problem-solving skills. The group also has an experiential curriculum, which includes prevention programs and activities to be implemented in their respective communities. The program has a reputation within the community as being one of the most strategically important initiatives currently underway.
"We're grateful to receive this generous grant from Bayer HealthCare," said Dr. Alan Kinniburgh, CEO of the National Hemophilia Foundation. "This contribution will help fund the National Youth Leadership Institute and will encourage and equip young adults to be active leaders in the bleeding disorders community."
In addition to the training provided to participants, NHF encourages local chapters to provide a liaison/mentor to the young participants to further ensure the success of local youth initiatives.
"Bayer is committed to supporting programs that focus on encouraging and developing young adults to become active leaders in the bleeding disorders community," said Terry Tenbrunsel, vice president of sales and marketing, Bayer HealthCare. "We are pleased to support the NHF and this important program as we drive toward our common goal of improving the lives of people living with hemophilia."
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately one in 5,000 males born in the United States has hemophilia.(i)
About Bayer HealthCare LLC
Bayer HealthCare LLC, an affiliate of Bayer HealthCare AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
(i)
http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=180&contentid=45&
rptname=bleeding
Bayer HealthCareCONTACT: Sreejit Mohan of Bayer HealthCare, +1-510-705-5477, orsreejit.mohan.b@bayer.com
